XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies Summary of Significant Accounting Principles (Tables)
 9 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Debt Securities, Held-to-maturity
The following is a summary of the net carrying amount, unrealized losses, and fair value of held-to-maturity securities by type and contractual maturity as of March 31, 2024 and June 30, 2023.

March 31, 2024
Amortized costUnrealized lossesFair value
Due within one year:
Corporate debt securities$2,500 $(11)$2,489 
U.S. government securities3,999 (18)3,981 
Total held-to-maturity securities$6,499 $(29)$6,470 

June 30, 2023
Amortized costUnrealized lossesFair value
Due within one year:
Commercial paper$15,982 $(10)$15,972 
Corporate debt securities16,298 (190)16,108 
U.S. government securities6,260 (69)6,191 
Total due within one year
38,540 (269)38,271 
Due between one and two years:
Corporate debt securities1,498 (35)1,463 
U.S. government securities2,999 (66)2,933 
Total due between one and two years4,497 (101)4,396 
Total held-to-maturity securities$43,037 $(370)$42,667 
Schedule of Other Nonoperating Income (Expense)
The following table summarizes the components of other (expense) income, net:
 Three Months Ended March 31, Nine Months Ended March 31,
2024202320242023
Gains (losses) on derivatives not designated as hedging instruments (1)
$9,071 $(2,428)$3,715 $2,021 
Currency-related (losses) gains, net (2)
(12,434)4,187 (2,071)10,217 
Other (losses) gains
(288)(382)733 (856)
Total other (expense) income, net
$(3,651)$1,377 $2,377 $11,382 
_____________________
(1) Includes realized and unrealized gains and losses on derivative currency forward and option contracts not designated as hedging instruments. For contracts not designated as hedging instruments, we realized losses of $349 and $838 for the three and nine months ended March 31, 2024, respectively, and realized gains of $4,876 and $35,864 for the three and nine months ended March 31, 2023, respectively. Refer to Note 4 for additional details relating to our derivative contracts.
(2) Currency-related (losses) gains, net primarily relates to significant non-functional currency intercompany financing relationships that we may change at times and are subject to currency exchange rate volatility. In addition, we have a cross-currency swap designated as a cash flow hedge which hedges the remeasurement of an intercompany loan. Refer to Note 4 for additional details relating to this cash flow hedge.
Schedule of Weighted Average Number of Shares
The following table sets forth the reconciliation of the weighted-average number of ordinary shares:
 Three Months Ended March 31, Nine Months Ended March 31,
 2024202320242023
Weighted average shares outstanding, basic
26,216,216 26,268,301 26,432,423 26,226,989 
Weighted average shares issuable upon exercise/vesting of outstanding share options/RSUs/warrants (1)(2)
— — 711,196 — 
Shares used in computing diluted net (loss) income per share attributable to Cimpress plc26,216,216 26,268,301 27,143,619 26,226,989 
Weighted average anti-dilutive shares excluded from diluted net (loss) income per share attributable to Cimpress plc (1)955,594 3,161,275 127,229 3,045,675 
___________________
(1) In the periods in which a net loss is recognized, the impact of share options, RSUs and warrants is excluded from shares used in computed diluted net (loss) income per share as it is anti-dilutive. Any equity awards that have a performance condition are not included in dilutive or anti-dilutive shares until the performance condition is met.
(2) On May 1, 2020, we entered into a financing arrangement which included 7-year warrants to purchase 1,055,377 of our ordinary shares with a strike price of $60 that have a potentially dilutive impact on our weighted average shares outstanding. For the three and nine months ended March 31, 2024, the average market price of our ordinary shares was higher than the strike price of the warrants. The weighted average anti-dilutive effect of the warrants was 309,000 for the three months ended March 31, 2024 (anti-dilutive due to our net loss position), and the weighted average dilutive effect of the warrants was 184,608 for the nine months ended March 31, 2024. For the three and nine months ended March 31, 2023, the average market price of our ordinary shares was lower than the strike price of the warrants; therefore, the total 1,055,377 outstanding warrants were considered anti-dilutive.